Inventor · disambiguated record
Andrei V. Blokhin
Also filed as: BLOKHIN ANDREI · BLOKHIN ANDREI V · VALASINAS ALDONIA L
25 granted patents·15 pending applications·468 citations·filing 2000–2024
96Inventor score
Files withARROWHEAD PHARMACEUTICALS INC13ARROWHEAD MADISON INC6CELLGATE INC5SLIL BIOMEDICAL CORP4PROGEN PHARMACEUTICALS INC3
Top patents by PatentIndex Score
40 records- 0198US8501930B2Peptide-based in vivo siRNA delivery systemROZEMA DAVID B·Filed 2011·Granted Aug 6, 2013·180 cites·18 claims
- 0295US8802773B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2013·Granted Aug 12, 2014·12 cites·22 claims
- 0395US8426554B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2011·Granted Apr 23, 2013·47 cites·14 claims
- 0494US6982351B2Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis thereforCELLGATE INC·Filed 2002·Granted Jan 3, 2006·38 cites·11 claims
- 0593US6809176B2Quinones as disease therapiesSLIL BIOMEDICAL CORP·Filed 2002·Granted Oct 26, 2004·40 cites·8 claims
- 0692US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 0792US7453011B2Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis thereforPROGEN PHARMACEUTICALS INC·Filed 2007·Granted Nov 18, 2008·17 cites·14 claims
- 0891US7235695B2Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis thereforFRYDMAN BENJAMIN·Filed 2005·Granted Jun 26, 2007·17 cites·26 claims
- 0991US6482943B1Quinones as disease therapiesSLIL BIOMEDICAL CORP·Filed 2000·Granted Nov 19, 2002·26 cites·1 claims
- 1087US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1186US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 1286US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 1385US9487556B2Polyconjugates for delivery of RNAi triggers to tumor cells in vivoARROWHEAD MADISON INC·Filed 2014·Granted Nov 8, 2016·6 cites·18 claims
- 1485US6794545B1Conformationally restricted polyamine analogs as disease therapiesSLIL BIOMEDICAL CORP·Filed 2000·Granted Sep 21, 2004·20 cites·20 claims
- 1584US7253207B2Quinones as disease therapiesCELLGATE INC·Filed 2004·Granted Aug 7, 2007·11 cites·21 claims
- 1684US7186825B2Conformationally restricted polyamine analogs as disease therapiesCELLGATE INC·Filed 2004·Granted Mar 6, 2007·15 cites·20 claims
- 1783US9107957B2Peptide-based in vivo siRNA delivery systemARROWHEAD MADISON INC·Filed 2013·Granted Aug 18, 2015·5 cites·14 claims
- 1883US7026347B2Porphyrin-polyamine conjugates for cancer therapyCELLGATE INC·Filed 2003·Granted Apr 11, 2006·14 cites·16 claims
- 1976US12116573B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 15, 2024·0 cites·3 claims
- 2076US9803201B2Disulfide-containing alkyne linking agentsARROWHEAD MADISON INC·Filed 2016·Granted Oct 31, 2017·1 cites·14 claims
- 2174US11840688B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 2269US9481661B2Disubstituted maleic anhydrides with altered kinetics of ring closureBLOKHIN ANDREI V·Filed 2012·Granted Nov 1, 2016·1 cites·4 claims
- 2365US2025223597A1Lipid conjugates for the delivery of therapeutic agents to cns tissueARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2463US10005815B2Biologically cleavable tetrapeptide linking agentsARROWHEAD MADISON INC·Filed 2016·Granted Jun 26, 2018·0 cites·21 claims
- 2563US2008269450A1Endosomolytic Poly-Beta-Aminoester PolymersWAKEFIELD DARREN H·Filed 2008·Application pending·0 cites
- 2662US10047361B2Disulfide-containing alkyne linking agentsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Aug 14, 2018·0 cites·12 claims
- 2762US2019211333A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2860US2009124832A1Oligoamine compounds and derivatives thereof for cancer therapyPROGEN PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2958US10059681B2Disubstituted maleic anhydrides with altered kinetics of ring closureARROWHEAD MADISON INC·Filed 2016·Granted Aug 28, 2018·0 cites·7 claims
- 3057US2019062748A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3157US2007161692A1Conformationally restricted polyamine analogs as disease therapiesCELLGATE INC·Filed 2006·Application pending·0 cites
- 3257US2023407313A1Integrin targeting ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3356US7491849B2Oligoamine compounds and derivatives thereof for cancer therapyPROGEN PHARMACEUTICALS INC·Filed 2004·Granted Feb 17, 2009·1 cites·21 claims
- 3456US2024175019A1Skeletal Muscle Delivery Platforms and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3554US2018258138A1Biologically Cleavable Tetrapeptide Linking AgentsARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3651US2017022497A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3746US2006276444A1Porphyrin-polyamine conjugates for cancer therapyFRYDMAN BENJAMIN·Filed 2006·Application pending·0 cites
- 3846US2003130356A1Oligoamine compounds and derivatives thereof for cancer therapySLIL BIOMEDICAL CORP·Filed 2002·Application pending·0 cites
- 3946US2006115848A1Nucleic acid end-labeling reagentsBLOKHIN ANDREI·Filed 2005·Application pending·0 cites
- 4038US2006008830A1Nucleic acid end-labeling reagentsSLATTUM PAUL M·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrei V. Blokhin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →